ReShape Lifesciences Inc. (NASDAQ:RSLS) shares traded 34.74% higher at $0.28 on Wall Street last session.
RSLS stock price is now 61.80% away from the 50-day moving average and -15.65% away from the 200-day moving average. The market capitalization of the company currently stands at $6.57M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
In other news, STANKOVICH THOMAS, Chief Financial Officer sold 131 shares of the company’s stock on Oct 25 ’23. The stock was sold for $35 at an average price of $0.27. Upon completion of the transaction, the Chief Financial Officer now directly owns 22,949 shares in the company, valued at $6425.72. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 11 ’23, Chief Financial Officer STANKOVICH THOMAS sold 39 shares of the business’s stock. A total of $36 was realized by selling the stock at an average price of $0.93. This leaves the insider owning 23,080 shares of the company worth $6462.4. A total of 11.27% of the company’s stock is owned by insiders.
During the past 12 months, ReShape Lifesciences Inc. has had a low of $0.14 and a high of $2.59. As of last week, the company has a debt-to-equity ratio of 0.05, a current ratio of 2.24, and a quick ratio of 1.26. The fifty day moving average price for RSLS is $0.17304 and a two-hundred day moving average price translates $0.33197 for the stock.
The latest earnings results from ReShape Lifesciences Inc. (NASDAQ: RSLS) was released for 2024-03-31. According to the Medical Devices Company, earnings per share came in at -1.08, beating analysts’ expectations of -1.79 by 0.71. This compares to -$1.56 EPS in the same period last year. The net profit margin was -130.99% and return on equity was -177.64% for RSLS. The company reported revenue of $1.94 million for the quarter, compared to $2.29 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -15.0 percent. For the current quarter, analysts expect RSLS to generate $2.21M in revenue.
